Is Zimmer Biomet Holdings Inc (ZBH) a Buy? The Stock Reaches All-Time High Today

July 17, 2017 - By Michael Collier

The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) reached all time high today, Jul, 17 and still has $141.87 target or 7.00 % above today’s $132.59 share price. This indicates more upside for the $27.47B company. This technical setup was reported by If the $141.87 PT is reached, the company will be worth $1.92 billion more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

About 943,324 shares traded. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 0.44% since July 17, 2016 and is downtrending. It has underperformed by 17.14% the S&P500.

Wall Street await Zimmer Biomet Holdings Inc (NYSE:ZBH) to release earnings on July, 27. Analysts forecast EPS of $2.10, up exactly $0.08 or 3.96 % from 2014’s $2.02 EPS. The expected ZBH’s profit could reach $435.08 million giving the stock 15.78 P/E in the case that $2.10 earnings per share is reported. After posting $2.13 EPS for the previous quarter, Zimmer Biomet Holdings Inc’s analysts now forecast -1.41 % negative EPS growth.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Among 23 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 17 have Buy rating, 2 Sell and 4 Hold. Therefore 74% are positive. Zimmer Biomet Holdings had 44 analyst reports since August 27, 2015 according to SRatingsIntel. On Monday, July 10 the stock rating was maintained by BMO Capital Markets with “Buy”. Canaccord Genuity maintained the shares of ZBH in report on Friday, September 4 with “Buy” rating. The stock has “Strong Buy” rating by Needham on Thursday, January 26. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has “Neutral” rating given on Tuesday, November 29 by Citigroup. The stock has “Buy” rating by Canaccord Genuity on Tuesday, July 11. Cantor Fitzgerald maintained Zimmer Biomet Holdings Inc (NYSE:ZBH) rating on Tuesday, July 11. Cantor Fitzgerald has “Hold” rating and $13700 target. The company was maintained on Friday, April 28 by Needham. As per Tuesday, November 1, the company rating was upgraded by Needham. The firm has “Overweight” rating by Barclays Capital given on Friday, April 29. The rating was maintained by UBS on Tuesday, August 2 with “Neutral”.

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: which released: “Jana Is Said to Hold Zimmer Biomet Talks After Building Stake” on July 13, 2017, also with their article: “Ex-Dividend Reminder: Luminex, Zimmer Biomet Holdings and Pembina Pipeline” published on June 19, 2017, published: “Zimmer Biomet Holdings, Inc. (ZBH) Ex-Dividend Date Scheduled for June 21, 2017” on June 20, 2017. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: and their article: “Zimmer Biomet Announces Leadership Transition” published on July 11, 2017 as well as‘s news article titled: “Jana granted regulatory clearance for Zimmer Biomet stake” with publication date: July 13, 2017.

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has market cap of $27.47 billion. The Company’s products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. It has a 54.28 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: